Sodium Alendronate – Bisphosphonate Therapy for Osteoporosis
Sodium Alendronate is a potent non-nitrogenous bisphosphonate that serves as a highly effective antiresorptive agent for the treatment of bone disorders. The mechanism of action of alendronate involves the selective suppression of osteoclast activity—the cells responsible for the destruction of the bone matrix. The drug incorporates into the bone structure and is released upon resorption by osteoclasts, leading to the disruption of their metabolism, inhibition of specific enzymes, and subsequent apoptosis. As a result of this process, the rate of bone turnover slows down, the balance between bone formation and resorption is restored, which leads to a significant increase in bone mineral density (BMD) and a decrease in the risk of pathological fractures.
The pharmacokinetic profile of alendronate is characterized by extremely low oral bioavailability (less than 1%), which is further reduced by food, beverages (other than water), or medications. After absorption, a portion of the drug is rapidly redistributed into the bones, while the remainder is excreted unchanged by the kidneys. Alendronate is not metabolized. The drug has an extremely long half-life in bone tissue, which provides a prolonged therapeutic effect even after treatment is discontinued. Alendronate does not bind to plasma proteins to a significant extent.
The drug is administered orally on an empty stomach. A crucial condition for administration is compliance with safety rules to prevent irritation of the esophageal mucosa: tablets must be taken with a full glass of plain water, and the patient must remain in an upright position for at least 30 minutes after intake.
Indications
Sodium alendronate is indicated for the prevention and treatment of conditions characterized by bone mass loss:
- Postmenopausal Osteoporosis: treatment and prevention of bone fractures, including fractures of the spine and hip.
- Osteoporosis in Men: to increase bone mass and prevent fractures.
- Glucocorticoid-induced Osteoporosis: prevention and treatment of bone density reduction caused by long-term systemic corticosteroid therapy.
- Paget's Disease (Osteitis Deformans): for the normalization of bone turnover and reduction of pain syndrome.
Dosage and administration
The dosing regimen is determined by the goal of therapy and the patient's individual clinical profile.
- Standard Dose: for osteoporosis—10 mg daily or 70 mg once weekly. For Paget's disease—40 mg daily for 6 months.
- Administration Method: the tablet should be taken strictly in the morning on an empty stomach, with a glass of plain water (at least 200 ml). It is forbidden to consume coffee, tea, juices, or milk with the medication.
- Safety Precautions: after taking the drug, it is strictly forbidden to lie down for 30–60 minutes. Furthermore, no food or other medications should be consumed during this period.
- Dose Adjustment: in patients with renal impairment (creatinine clearance less than 35 ml/min), the use of alendronate is not recommended.
